apellis

Building a Leader in Biotech 
In anticipation of its initial public offering (IPO), clinical-stage biotech company Apellis Pharmaceuticals asked Denterlein to develop and execute a comprehensive, fully-integrated communications strategy designed to raise awareness of the company and its development of novel therapeutic compounds to treat rare diseases, such as Geographic Atrophy and PNH.

100+

Earned media 
placements among 
key business, trade, and regional/local press

125%

Average quarter over quarter growth in social media followers across Twitter and LinkedIn

6K

Unique social media engagements across the company's Twitter
and LinkedIn

Establishing a Position in the Marketplace
Our team devised and implemented a communications program based on strategic positioning and messaging, producing a steady cadence of "on the record" news, securing executive/leadership visibility opportunities, and launching and managing Apellis’ social media channels.

Apellis Nasdaq-1

“The work we do daily with clients on the leading edge of developing life changing technologies and innovations in healthcare is truly rewarding.”

Tully Circle
Tully Nicholas
Vice President

Want to work with us?

Get in touch!